Gene therapy for allergic diseases

Current Gene Therapy

Volumn 9, Issue 3, 2009, Pages 185-191

  Chuang, Ya Hui ^a   Yang, Yao Hsu ^a   Wu, Si Jie ^a   Chiang, Bor Luen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Allergen specific immunotherapy; Allergic disease; Cytokine; Gene therapy; Regulatory T cell; TH2; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; CD40 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOTHERAPY; REVIEW; TH1 CELL; TH2 CELL; ANIMAL; DESENSITIZATION; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; METHODOLOGY; PATHOLOGY;

ANIMALS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; GENE THERAPY; HUMANS; HYPERSENSITIVITY; TH2 CELLS;

EID: 70349579521     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309788488604     Document Type: Review

References (70)

1. Floistrup H, Swartz J, Bergstrom A, et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006; 117: 59-66.
2. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761-71.
3. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8: 218-30.
4. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24: 147-74.
5. Xystrakis E, Urry Z, Hawrylowicz CM. Regulatory T cell therapy as individualized medicine for asthma and allergy. Curr Opin Allergy Clin Immunol 2007; 7: 535-41.
6. Larche M. Regulatory T cells in allergy and asthma. Chest 2007; 132: 1007-14.
7. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005; 5: 271-83.
8. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 2005; 202: 1459-63.
9. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
10. Wan YY, Flavell RA. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 2007; 220: 199-213.
11. Kitani A, Fuss I, Nakamura K, et al. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003; 198: 1179-88.
12. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-15.
13. Cosmi L, Liotta F, Angeli R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004; 103: 3117-21.
14. Grindebacke H, Wing K, Andersson AC, et al. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004; 34: 1364-72.
15. Hartl D, Koller B, Mehlhorn AT, et al. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol 2007; 119: 1258-66.
16. Mucida D, Kutchukhidze N, Erazo A, et al. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 2005; 115: 1923-33.
17. Curotto de Lafaille MA, Kutchukhidze N, Shen S, et al. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 2008; 29: 114-26.
18. Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol 2008; 20: 697-702.
19. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003; 97: 726-33.
20. Hashimoto T, Akiyama K, Kobayashi N, Mori A. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy Immunol 2005; 137 (Suppl 1): 51-4.
21. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17: 375-87.
22. Schnyder-Candrian S, Togbe D, Couillin I, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203: 2715-25.
23. Chua KY, Huangfu T, Liew LN. DNA vaccines and allergic diseases. Clin Exp Pharmacol Physiol 2006; 33: 546-50.
24. Factor P. Gene therapy for asthma. Mol Ther 2003; 7: 148-52.
25. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108: 921-8.
26. Flicker S, Steinberger P, Norderhaug L, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002; 32: 2156-62.
27. Wolf BL, Hamilton RG. Near-fatal anaphylaxis after Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1998; 102: 527-8.
28. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2: 540-4.
29. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 5141-5.
30. Hartl A, Hochreiter R, Stepanoska T, Ferreira F, Thalhamer J. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a. Allergy 2004; 59: 65-73.
31. Hartl A, Kiesslich J, Weiss R, et al. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J Allergy Clin Immunol 1999; 103: 107-13.
32. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol 2001; 166: 3612-21.
33. Maecker HT, Hansen G, Walter DM, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001; 166: 959-65.
34. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91.
35. Jacquet A, Magi M, Haumont M, et al. Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1. Clin Exp Allergy 2003; 33: 218-25.
36. Tan LK, Huang CH, Kuo IC, Liew LM, Chua KY. Intramuscular immunization with DNA construct containing Der p 2 and signal peptide sequences primed strong IgE production. Vaccine 2006; 24: 5762-71.
37. Gabler M, Scheiblhofer S, Kern K, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006; 118: 734-41.
38. Jin H, Kang Y, Zhao L, et al. Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines. J Immunol 2008; 180: 5360-72.
39. Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 1998; 102: 469-75.
40. Toda M, Sato H, Takebe Y, et al. Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology 2000; 99: 179-86.
41. Horner AA, Takabayashi K, Beck L, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002; 110: 413-20.
42. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-9.
43. Chiang DJ, Ye YL, Chen WL, et al. Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 2003; 168: 575-80.
44. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109: 455-62.
45. Youn CJ, Miller M, Baek KJ, et al. Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol 2004; 173: 7556-64.
46. Horner AA, Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002; 110: 706-12.
47. Huang FT, Lim LH, Chua KY. Efficacy evaluation of Der p 1 DNA vaccine for allergic asthma in an experimental mouse model. Vaccine 2006; 24: 4576-81.
48. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999; 18: 765-77.
49. Behera AK, Kumar M, Lockey RF, Mohapatra SS. Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther 2002; 13: 1697-709.
50. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998; 28: 413-23.
51. Lee YL, Ye YL, Yu CI, et al. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther 2001; 12: 2065-79.
52. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
53. Walter DM, Wong CP, DeKruyff RH, et al. Il-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity. J Immunol 2001; 166: 6392-8.
54. Ye YL, Lee YL, Chuang ZJ, et al. Dendritic cells modulated by cytokine-expressing adenoviruses alleviate eosinophilia and airway hyperresponsiveness in an animal model of asthma. J Allergy Clin Immunol 2004; 114: 88-96.
55. Fu CL, Chuang YH, Chau LY, Chiang BL. Effects of adenovirus-expressing IL-10 in alleviating airway inflammation in asthma. J Gene Med 2006; 8: 1393-9.
56. Hansen G, McIntire JJ, Yeung VP, et al. CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest 2000; 105: 61-70.
57. Chuang YH, Fu CL, Lo YC, Chiang BL. Adenovirus expressing Fas ligand gene decreases airway hyper-responsiveness and eosinophilia in a murine model of asthma. Gene Ther 2004; 11: 1497-505.
58. Chuang YH, Suen JL, Chiang BL. Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. J Mol Med 2006; 84: 595-603.
59. Wang CC, Fu CL, Yang YH, et al. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther 2006; 13: 1414-21.
60. Suzuki M, Zheng X, Zhang X, et al. Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol 2008; 180: 8461-9.
61. Ritprajak P, Hashiguchi M, Azuma M. Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther 2008; 16: 1323-30.
62. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-96.
63. Nakamura Y, Christodoulopoulos P, Cameron L, et al. Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge. J Allergy Clin Immunol 2000; 105: 1146-52.
64. Kiwamoto T, Ishii Y, Morishima Y, et al. Transcription factors Tbet and GATA-3 regulate development of airway remodeling. Am J Respir Crit Care Med 2006; 174: 142-51.
65. Finotto S, De Sanctis GT, Lehr HA, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001; 193: 1247-60.
66. Lee CC, Huang HY, Chiang BL. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther 2008; 16: 60-5.
67. Lee CC, Chiang BL. RNA interference: new therapeutics in allergic diseases. Curr Gene Ther 2008; 8: 236-46.
68. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115-9.
69. Huang HY, Lee CC, Chiang BL. Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness. Gene Ther 2008; 15: 660-7.
70. Fu CL, Ye YL, Lee YL, Chiang BL. Effects of overexpression of IL-10, IL-12, TGF-beta and IL-4 on allergen induced change in bronchial responsiveness. Respir Res 2006; 7: 72.